Clinical trials: Dissection of Aorta, Thoracic
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
Managed Access Programs for LDK378, Ceritinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
- Trial name
- NCT05100134
- Testing
- ceritinib
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Rapid Absorbance-based Detection of Inner Cheek Cell Abnormalities Using Light Spectroscopy for Risk Evaluation of Lung Cancer to Enable Critical Decision Support in Targeted Patient Populations
Overview Sierra Medical is at the forefront of early detection of lung cancer by creating AIR-DS, a non-invasive early detection test.
- Trial name
- RADICAL-REACT (NCT07051044)
- Testing
- AIR-DS
- Where
- 2 sites in United Kingdom
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sierra Medical Ltd.
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to characterize the effect of repeated oral administration of TAK-788 160 milligram (mg) once daily on the single oral and intravenous dose pharmacokinetics (PK) of midazolam.
- Trial name
- NCT04051827
- Testing
- Midazolam, TAK-788
- Where
- 8 sites in Australia, Netherlands and 1 more
- Volunteers
- 26 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non Small Cell Lung Carcinoma
ZD6474 Phase IIa Dose Finding Multicentre Study
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
- Trial name
- NCT00252746
- Testing
- ZD6474 (vandetanib) 100mg, ZD6474 (vandetanib) 200mg, ZD6474 (vandetanib) 300mg
- Where
- 7 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Genzyme, a Sanofi Company
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent…
- Trial name
- IPSOS (NCT03191786)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Vinorelbine, Gemcitabine
- Where
- 91 sites in Argentina, Belgium and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non Small Cell Lung
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.
- Trial name
- NCT00160069
- Testing
- Sagopilone (BAY86-5302, ZK 219477)
- Where
- 17 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Bayer
Advanced Thymic Carcinoma
Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy
Indication: Patients with advanced recurrent or metastatic thymic carcinoma. Phase IIa (China only):Approximately 6 patients. Phase IIb (China only):Approximately 54 patients.
- Trial name
- NCT07824505
- Testing
- lucitanib 15 mg QD, lucitanib 10 mg QD
- Where
- 16 sites in China
- Volunteers
- 74 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Soft Tissue Sarcoma, Colorectal Cancer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma
- Trial name
- NCT03957096
- Testing
- SGN-CD47M
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seagen Inc.
Non-Small-Cell Lung Cancer
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
This was a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of the ALK inhibitor LDK378 when used as single agent in patients with ALK-rearranged stage IIIB or IV NSCLC previously treated…
- Trial name
- NCT02450903
- Testing
- LDK378
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms, Breast Neoplasms
A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer
CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and…
- Conditions
- Colorectal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
- Trial name
- NCT00034827
- Testing
- CI-1040
- Where
- 30 sites in United States
- Volunteers
- 172 people
- Sponsor
- Pfizer
Thoracic Surgery, Pneumonectomy
Personalized Postoperative Pain Management Following Thoracic Surgery in Adults
The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research.
- Conditions
- Thoracic Surgery, Pneumonectomy, Lobectomy, Segmentectomy
- Trial name
- NCT05525923
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- OpalGenix, Inc
EGFR Gene Mutation
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
- Trial name
- NCT03046992
- Testing
- YH25448
- Where
- 16 sites in South Korea
- Volunteers
- 224 people
- Sponsor
- Yuhan Corporation
Non-small-cell Lung Cancer
A Study of ARQ 197 in Combination With Erlotinib
This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in patients with advanced/recurrent non-small-cell lung cancer.
- Trial name
- NCT01069757
- Testing
- ARQ 197 and Erlotinib
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Non Small Cell Lung Cancer
131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)
The aim of this feasibility study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with radiochemotherapy, for the treatment of patients with newly diagnosed…
- Trial name
- NCT01124812
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Philogen S.p.A.
Merkel Cell Carcinoma, Small Cell Lung Cancer
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell…
- Trial name
- NCT04590781
- Testing
- XmAb18087, XmAb18087 ± Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Xencor, Inc.
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Nonsquamous Nonsmall Cell Neoplasm of Lung
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed…
- Trial name
- DENALI (NCT02259582)
- Testing
- Pemetrexed, Carboplatin, demcizumab
- Where
- 45 sites in United States, Australia and 3 more
- Volunteers
- 82 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07558200
- Testing
- Intervention1：FXB0871, Intervention2：FXB0871, Intervention3：FXB0871
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-small-Cell Lung Cancer
Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid
The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.
- Trial name
- NCT03413358
- Testing
- Sheng Bai oral liquid, Platinum-based two medicine (carboplatin / cisplatin) .
- Where
- China
- Volunteers
- 240 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.